Octreotide and lanreotide treatment in active acromegaly.
Cannavò
S
S
Fazio
R
R
Squadrito
S
S
Trimarchi
F
F
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000681:Amylases / Q000097:blood; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D015282:Octreotide / Q000009:adverse effects*; D010195:Pancreatitis / Q000139:chemically induced*; D010456:Peptides, Cyclic / Q000009:adverse effects*; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives*
D005765:Gastrointestinal Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D000681:Amylases; D015282:Octreotide